Affiliation:
1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd., Hangzhou 310003, China
2. Jinan Microecological Biomedicine Shandong Laboratory, Jinan 250000, China
Abstract
Hesperetin (HT) is a type of citrus flavonoid with various pharmacological activities, including anti-tumor, anti-inflammation, antioxidant, and neuroprotective properties. However, the role and mechanism of HT in ulcerative colitis (UC) have been rarely studied. Our study aimed to uncover the beneficial effects of HT and its detailed mechanism in UC. Experimental colitis was induced by 2.5% dextran sodium sulfate (DSS) for seven days. HT ameliorated DSS-induced colitis in mice, showing marked improvement in weight loss, colon length, colonic pathological severity, and the levels of TNFα and IL6 in serum. A combination of informatics, network pharmacology, and molecular docking identified eight key targets and multi-pathways influenced by HT in UC. As a highlight, the experimental validation demonstrated that PTGS2, a marker of ferroptosis, along with other indicators of ferroptosis (such as ACSL4, Gpx4, and lipid peroxidation), were regulated by HT in vivo and in vitro. Additionally, the supplement of HT increased the diversity of gut microbiota, decreased the relative abundance of Proteobacteria and Gammaproteobacteria, and restored beneficial bacteria (Lachnospiraceae_NK4A136_group and Prevotellaceae_UCG-001). In conclusion, HT is an effective nutritional supplement against experimental colitis by suppressing ferroptosis and modulating gut microbiota.
Funder
Shandong Provincial Laboratory Project
Reference72 articles.
1. The four epidemiological stages in the global evolution of inflammatory bowel disease;Kaplan;Nat. Rev. Gastroenterol. Hepatol.,2021
2. Lautenschlager, S.A., Barry, M.P., Rogler, G., Biedermann, L., Schreiner, P., Siebenhüner, A.R., Abdelrahman, K., Ademi, G., Aepli, P., and Thomas, A. (2023). Lifestyle factors associated with inflammatory bowel disease: Data from the Swiss IBD cohort study. BMC Gastroenterol., 23.
3. The economic burden of inflammatory bowel disease;Lancet Gastroenterol. Hepatol.,2023
4. Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: A cross-sectional study;Matsuoka;J. Gastroenterol.,2023
5. A Biological Perspective of TLR8 Signaling in Host Defense and Inflammation;Bian;Infect. Microbes Dis.,2023